Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Core Insights - Abpro Holdings, Inc. and Celltrion have presented preclinical data for ABP-102/CT-P72, a bispecific T-cell engager targeting HER2-overexpressing tumors, at the AACR Annual Meeting 2025, indicating its potential to outperform existing HER2-targeted therapies in efficacy and safety [1][2][3] Company Overview - Abpro is a biotechnology company focused on next-generation antibody therapies for severe diseases, utilizing its proprietary DiversImmune® platform [9] - Celltrion is a leading biopharmaceutical company based in South Korea, specializing in innovative therapeutics and has a global presence in over 110 countries [11] Product Development - ABP-102/CT-P72 is designed to selectively target HER2-overexpressing tumor cells while minimizing toxicity in normal tissues, representing a significant advancement in bispecific antibody therapies [2][6] - The product is co-developed with Celltrion and aims to address toxicity barriers that have previously limited HER2-targeted T-cell engagers [3][7] Preclinical Findings - Preclinical data suggest that ABP-102/CT-P72 achieves potent cytotoxicity in HER2-overexpressing cancer models while significantly reducing activity against HER2-low cells, addressing limitations of prior therapies [8] - In vivo studies indicate that ABP-102/CT-P72 can achieve up to a two-fold increase in tumor suppression compared to a benchmark HER2 x CD3 bispecific antibody [8] - The engineered design of ABP-102/CT-P72 minimizes cytokine-related toxicities and has shown improved tolerability in dose escalation studies, suggesting a broader therapeutic window [5][8] Clinical Development Plans - Clinical trials for ABP-102/CT-P72 are planned to commence in the first half of 2026, with the aim of bringing this promising therapy to patients with HER2-driven cancers [5][6]